Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Mitomycin and Cisplatin for Gastric Cancer
NCT02891447Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2016
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c and cisplatin in gastric adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival. Started Sep 2016; status: completed.
02
Drugs
mitomycin ccisplatin
03
Conditions
gastric adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02891447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891447.